Search
Xeris Biopharma Holdings Inc
XERSAdd to Watchlist
6.950USD
+0.050+0.72%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
90.22P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Xeris Biopharma Holdings Inc is 8.57, ranking 28 out of 157 in the Pharmaceuticals industry. The average price target is 10.00, with a high of 18.00 and a low of 8.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
11.286
Target Price
+62.38%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Xeris Biopharma Holdings Inc
XERS
7
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Xeris Biopharma Holdings Inc's expected revenue for the next quarter?
Xeris Biopharma Holdings Inc's expected revenue is 90.29M.
What is Xeris Biopharma Holdings Inc's price target?
Analysts forecast that Xeris Biopharma Holdings Inc's price target is USD 10.00, with the highest forecast at USD 18.00 and the lowest forecast at USD 8.00.
What is the analyst rating for Xeris Biopharma Holdings Inc?
Based on the ratings of Xeris Biopharma Holdings Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
